Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

ABSTRACT:

Purpose

To provide 2-year results comparing anti-vascular endothelial growth factor (VEGF) agents for center-involved diabetic macular edema (DME) using a standardized follow-up and retreatment regimen.

Design

Randomized clinical trial.

Participants

Six hundred sixty participants with visual acuity (VA) impairment from DME.

Methods

Randomization to 2.0-mg aflibercept, 1.25-mg repackaged (compounded) bevacizumab, or 0.3-mg ranibizumab intravitreous injections performed up to monthly using a protocol-specific follow-up and retreatment regimen. Focal/grid laser photocoagulation was added after 6 months if DME persisted. Visits occurred every 4 weeks during year 1 and were extended up to every 4 months thereafter when VA and macular thickness were stable.

Main o

SUBMITTER: Wells JA 

PROVIDER: S-EPMC4877252 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature